A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant B-NHL

Study title: 
A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant B-NHL
Long title: 
A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant B-NHL
Date receipt dossier: 
2 Dec 2019
EU record number: 
MB-CART2019.1
EudraCT number: 
2018-001253-27
Pharmaceutical study code: 
MB-CART2019.1
Company / Sponsor: 
Miltenyi Biotech GmbH
Phase: 
I/II a
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
relapsed and resistant B-NHL
Therapeutic approach: 
Immunotherapy
Genetic modification: 
CD19 and CD20 chimeric antigen receptor
Method of transfer of nucleic acid of interest: 
lentiviral vectors
Administered biological material: 
Autologous T-cells transduced with lentiviral vectors expressing CD19/CD20 CAR
Route of administration: 
Intravenous
Locations in Belgium: 
UZ Gent
Type of procedure: 
Contained use only
Current status: 
Authorized